|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.52 USD | +0.73% |
|
-0.21% | -0.33% |
| Jan. 12 | Zoetis CEO on Animal Health, Vaccines and Beef Prices | MT |
| Jan. 12 | Zoetis Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 10:30 AM |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 11.43 | 12.77 | 12.73 | 13.15 | 14.87 | |||||
Return on Total Capital | 13.98 | 15.58 | 15.36 | 15.74 | 18.1 | |||||
Return On Equity % | 50.49 | 48.91 | 47.19 | 49.82 | 51.14 | |||||
Return on Common Equity | 50.58 | 49.01 | 47.25 | 49.86 | 50.91 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 69.47 | 70.49 | 69.73 | 70.06 | 70.64 | |||||
SG&A Margin | 25.66 | 25.73 | 24.86 | 25.18 | 25.04 | |||||
EBITDA Margin % | 40.39 | 41.24 | 41.24 | 40.82 | 41.37 | |||||
EBITA Margin % | 37.92 | 38.77 | 38.73 | 38.12 | 38.49 | |||||
EBIT Margin % | 34.47 | 36.15 | 36.34 | 35.96 | 36.66 | |||||
Income From Continuing Operations Margin % | 24.51 | 26.16 | 26.13 | 27.39 | 26.97 | |||||
Net Income Margin % | 24.54 | 26.2 | 26.16 | 27.43 | 26.86 | |||||
Net Avail. For Common Margin % | 24.54 | 26.2 | 26.16 | 27.43 | 26.86 | |||||
Normalized Net Income Margin | 19.39 | 20.71 | 21.08 | 21.46 | 21.67 | |||||
Levered Free Cash Flow Margin | 20.7 | 18.11 | 14.53 | 14.95 | 25.63 | |||||
Unlevered Free Cash Flow Margin | 22.86 | 19.91 | 16.24 | 16.7 | 27.15 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.53 | 0.57 | 0.56 | 0.58 | 0.65 | |||||
Fixed Assets Turnover | 2.95 | 3.11 | 2.9 | 2.66 | 2.62 | |||||
Receivables Turnover (Average Receivables) | 6.36 | 7.25 | 6.88 | 6.78 | 7.07 | |||||
Inventory Turnover (Average Inventory) | 1.34 | 1.29 | 1.15 | 1.04 | 1.12 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.05 | 3.86 | 2.37 | 3.36 | 1.75 | |||||
Quick Ratio | 2.13 | 2.58 | 1.51 | 1.77 | 0.97 | |||||
Operating Cash Flow to Current Liabilities | 0.98 | 1.23 | 0.6 | 1.25 | 0.87 | |||||
Days Sales Outstanding (Average Receivables) | 57.55 | 50.37 | 53.03 | 53.81 | 51.8 | |||||
Days Outstanding Inventory (Average Inventory) | 272.79 | 282.38 | 318.44 | 350.23 | 327.89 | |||||
Average Days Payable Outstanding | 61.49 | 62.92 | 53.52 | 53.63 | 62.79 | |||||
Cash Conversion Cycle (Average Days) | 268.85 | 269.82 | 317.96 | 350.41 | 316.91 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 197.19 | 149.47 | 185.44 | 137.01 | 143.17 | |||||
Total Debt / Total Capital | 66.35 | 59.92 | 64.97 | 57.81 | 58.88 | |||||
LT Debt/Equity | 179.57 | 148.5 | 153.76 | 135.96 | 113.77 | |||||
Long-Term Debt / Total Capital | 60.42 | 59.53 | 53.87 | 57.37 | 46.79 | |||||
Total Liabilities / Total Assets | 72.28 | 67.31 | 70.5 | 65.06 | 66.5 | |||||
EBIT / Interest Expense | 9.96 | 12.55 | 13.29 | 12.85 | 15.08 | |||||
EBITDA / Interest Expense | 11.99 | 14.67 | 15.42 | 14.96 | 17.42 | |||||
(EBITDA - Capex) / Interest Expense | 10.03 | 12.54 | 12.76 | 11.9 | 14.51 | |||||
Total Debt / EBITDA | 2.69 | 2.07 | 2.4 | 1.91 | 1.74 | |||||
Net Debt / EBITDA | 1.38 | 1 | 1.35 | 1.34 | 1.24 | |||||
Total Debt / (EBITDA - Capex) | 3.21 | 2.42 | 2.89 | 2.41 | 2.09 | |||||
Net Debt / (EBITDA - Capex) | 1.66 | 1.17 | 1.62 | 1.69 | 1.48 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 6.63 | 16.49 | 3.91 | 5.74 | 8.33 | |||||
Gross Profit, 1 Yr. Growth % | 6.72 | 18.2 | 2.79 | 6.25 | 9.22 | |||||
EBITDA, 1 Yr. Growth % | 8.62 | 18.95 | 3.9 | 4.68 | 9.78 | |||||
EBITA, 1 Yr. Growth % | 8.44 | 19.12 | 3.78 | 4.09 | 9.4 | |||||
EBIT, 1 Yr. Growth % | 9.73 | 22.16 | 4.45 | 4.63 | 10.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 9.07 | 24.33 | 3.79 | 10.85 | 6.67 | |||||
Net Income, 1 Yr. Growth % | 9.2 | 24.36 | 3.78 | 10.88 | 6.06 | |||||
Normalized Net Income, 1 Yr. Growth % | 8.38 | 24.41 | 5.78 | 7.62 | 9.4 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 9.97 | 24.85 | 5.15 | 12.92 | 7.89 | |||||
Accounts Receivable, 1 Yr. Growth % | -6.72 | 11.85 | 7.24 | 7.33 | 0.92 | |||||
Inventory, 1 Yr. Growth % | 15.46 | 18.12 | 21.94 | 9.34 | -10.06 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.45 | 8.73 | 14.21 | 15.81 | 5.11 | |||||
Total Assets, 1 Yr. Growth % | 17.88 | 2.14 | 7.37 | -4.28 | -0.34 | |||||
Tangible Book Value, 1 Yr. Growth % | -64.21 | -160.94 | -27.91 | 222.58 | 2.11 | |||||
Common Equity, 1 Yr. Growth % | 39.18 | 20.54 | -3.04 | 13.44 | -4.54 | |||||
Cash From Operations, 1 Yr. Growth % | 18.44 | 4.09 | -13.6 | 23.06 | 25.5 | |||||
Capital Expenditures, 1 Yr. Growth % | -1.52 | 5.3 | 22.85 | 24.91 | -10.52 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 22.47 | 6.36 | -19.43 | 8.84 | 85.66 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 20.39 | 5.43 | -17.84 | 8.77 | 76.08 | |||||
Dividend Per Share, 1 Yr. Growth % | 21.95 | 25 | 30 | 15.38 | 15.2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.05 | 11.45 | 10.02 | 4.82 | 7.03 | |||||
Gross Profit, 2 Yr. CAGR % | 8.73 | 12.31 | 10.23 | 4.51 | 7.72 | |||||
EBITDA, 2 Yr. CAGR % | 11.31 | 13.67 | 11.17 | 4.29 | 7.2 | |||||
EBITA, 2 Yr. CAGR % | 11.17 | 13.66 | 11.19 | 3.94 | 6.71 | |||||
EBIT, 2 Yr. CAGR % | 10.31 | 15.78 | 12.96 | 4.54 | 7.5 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 7.19 | 16.45 | 13.59 | 7.26 | 8.74 | |||||
Net Income, 2 Yr. CAGR % | 7.1 | 16.53 | 13.6 | 7.27 | 8.44 | |||||
Normalized Net Income, 2 Yr. CAGR % | 9.85 | 16.12 | 14.72 | 6.7 | 8.5 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.04 | 17.17 | 14.58 | 8.97 | 10.37 | |||||
Accounts Receivable, 2 Yr. CAGR % | -1.12 | 2.14 | 9.52 | 7.28 | 4.07 | |||||
Inventory, 2 Yr. CAGR % | 8.18 | 16.78 | 20.02 | 15.47 | -0.84 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 20.16 | 10.57 | 11.44 | 15.01 | 10.33 | |||||
Total Assets, 2 Yr. CAGR % | 12.37 | 9.73 | 4.72 | 1.38 | -2.33 | |||||
Tangible Book Value, 2 Yr. CAGR % | -48.35 | -53.29 | -33.72 | 52.5 | 81.49 | |||||
Common Equity, 2 Yr. CAGR % | 31.34 | 29.52 | 8.11 | 4.88 | 4.06 | |||||
Cash From Operations, 2 Yr. CAGR % | 8.98 | 11.03 | -5.17 | 3.11 | 24.28 | |||||
Capital Expenditures, 2 Yr. CAGR % | 15.77 | 1.83 | 13.74 | 23.88 | 5.72 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 9.47 | 15.12 | -7.86 | -6.35 | 42.15 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 9.11 | 13.5 | -7.31 | -5.47 | 38.39 | |||||
Dividend Per Share, 2 Yr. CAGR % | 25.99 | 23.47 | 27.48 | 22.47 | 15.29 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 7.94 | 10.11 | 8.88 | 8.58 | 5.98 | |||||
Gross Profit, 3 Yr. CAGR % | 9.35 | 11.8 | 9.05 | 8.88 | 6.05 | |||||
EBITDA, 3 Yr. CAGR % | 11.08 | 13.8 | 10.31 | 8.96 | 6.09 | |||||
EBITA, 3 Yr. CAGR % | 11.05 | 13.76 | 10.26 | 8.77 | 5.72 | |||||
EBIT, 3 Yr. CAGR % | 9.6 | 14.13 | 11.87 | 10.11 | 6.47 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 23.81 | 12.62 | 12.06 | 12.67 | 7.06 | |||||
Net Income, 3 Yr. CAGR % | 23.77 | 12.57 | 12.12 | 12.69 | 6.87 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.6 | 14.5 | 12.57 | 12.3 | 7.59 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 25.02 | 13.38 | 13.02 | 14.02 | 8.61 | |||||
Accounts Receivable, 3 Yr. CAGR % | 0.5 | 3.03 | 3.81 | 8.78 | 5.12 | |||||
Inventory, 3 Yr. CAGR % | 4.49 | 11.4 | 18.48 | 16.35 | 6.24 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 18.6 | 16.22 | 11.77 | 12.88 | 11.61 | |||||
Total Assets, 3 Yr. CAGR % | 16.59 | 8.85 | 8.94 | 1.63 | 0.8 | |||||
Tangible Book Value, 3 Yr. CAGR % | -14.3 | -45.42 | -46.02 | 12.33 | 33.41 | |||||
Common Equity, 3 Yr. CAGR % | 28.65 | 27.63 | 17.61 | 9.86 | 1.64 | |||||
Cash From Operations, 3 Yr. CAGR % | 16.46 | 7.33 | 2.13 | 3.44 | 10.09 | |||||
Capital Expenditures, 3 Yr. CAGR % | 26.46 | 12.17 | 8.4 | 17.35 | 11.15 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 10.93 | 6.88 | 3.39 | -2.6 | 17.64 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 10.81 | 6.49 | 2.97 | -2.24 | 16.31 | |||||
Dividend Per Share, 3 Yr. CAGR % | 23.96 | 25.66 | 25.61 | 23.31 | 20 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 6.97 | 9.73 | 8.77 | 7.96 | 8.14 | |||||
Gross Profit, 5 Yr. CAGR % | 8.5 | 11.08 | 9.7 | 8.82 | 8.52 | |||||
EBITDA, 5 Yr. CAGR % | 13.13 | 13.58 | 11.12 | 9.9 | 9.06 | |||||
EBITA, 5 Yr. CAGR % | 13.85 | 14.1 | 11.11 | 9.72 | 8.83 | |||||
EBIT, 5 Yr. CAGR % | 12.82 | 13.94 | 10.93 | 10.19 | 10.1 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 37 | 19.95 | 19.62 | 10.44 | 10.72 | |||||
Net Income, 5 Yr. CAGR % | 37.03 | 19.93 | 19.6 | 10.42 | 10.63 | |||||
Normalized Net Income, 5 Yr. CAGR % | 12.57 | 14.8 | 11.62 | 11.31 | 10.92 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 38.2 | 20.95 | 20.74 | 11.59 | 11.96 | |||||
Accounts Receivable, 5 Yr. CAGR % | 1.57 | 4.41 | 4.01 | 4.71 | 3.92 | |||||
Inventory, 5 Yr. CAGR % | 2.1 | 5.07 | 10.44 | 13.01 | 10.34 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.87 | 13.52 | 15.68 | 15.74 | 11.19 | |||||
Total Assets, 5 Yr. CAGR % | 11.45 | 12.69 | 11.69 | 5.8 | 4.28 | |||||
Tangible Book Value, 5 Yr. CAGR % | -16.63 | -20.54 | -22.67 | -17.67 | -12.33 | |||||
Common Equity, 5 Yr. CAGR % | 28.69 | 25.03 | 20 | 17.99 | 11.99 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.21 | 25.42 | 7.27 | 5.62 | 10.47 | |||||
Capital Expenditures, 5 Yr. CAGR % | 15.13 | 17.17 | 21.21 | 16.71 | 7.32 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 8.3 | 17.25 | 3.01 | 2.07 | 17.43 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 8.72 | 15.94 | 3.19 | 2.17 | 15.9 | |||||
Dividend Per Share, 5 Yr. CAGR % | 19.23 | 21.35 | 25.35 | 24.37 | 21.37 |
- Stock Market
- Equities
- ZTS Stock
- Financials Zoetis Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















